Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).

The Nifty50 had a gap-up opening at 23,216.50 on Tuesday and ended the day at 23,176.05, up 0.39% from Monday's close.

Shares of Biocon surged as much as 5 per cent during the trading session on Monday after the USFDA cleared Malaysia unit to ...